arry 520 and 614, and the stock sells off. See that CELG presented exceptional data on mds, but it is likely the upgrade that made it pop. No reason for this sell off today, and with over 50 arry drugs in phase 2, and a half dozen in phase 3, it is only a matter of time. Novartis or Astra will buy arry at no less than 4 X current market cap. With the potential for up to 2 billion in revenue here, and a robust 50 phase study pipeline it is a low risk, high reward buy out. It will happen, not sure when but I figure arry is taken out before year end 2014.
Both Astra and Novartis will owe Arry the equivalent of the current market cap upon approval and milestones, so a buyout saves either company about 600 million or at a 5.50-6.00 discount. If they offer 20.00 bucks the buyer gets the company for 15.00 after factoring the royalty savings.
The REAL question is would the shareholders really want to sell at such a deep discount to potential 2016 market cap which should be in the 8-10 billion range?